Diabetes is a prominent risk factor for the development of cardiovascular disease. Patients with diabetes carry 4 times greater risk of cardiovascular mortality, and constitute a disproportionate cohort of large scale heart failure studies. The interaction between diabetes and heart failure is diverse, with many pathways having been implicated. One factor in common between the conditions is impairment of the cardiac sympathetic nervous system (SNS), characterized initially by hyperactivity and elevated norepinephrine spillover, eventually culminating in sympathetic denervation and reduced capacity for norepinephrine release. Acute sympathetic activation evokes increased heart rate and contractility, whereas chronic activation can depress SNS sensitivity.

Continued advances in molecular imaging have led to the characterization of multiple radiotracers for the interrogation of the cardiac SNS. In a preclinical setting, longitudinal non-invasive imaging studies of sympathetic regulation during the development of diabetes and subsequent left ventricular dysfunction can provide important mechanistic insights into cardiac pathology. Long-term clinical application of imaging techniques could be used to stratify cardiovascular risk among diabetic patients.

**Sympathetic nervous system signal transduction**

The autonomic nervous system is the primary...
Imaging cardiac SNS in diabetes

Extrinsic control of heart rate and contractility.

Sympathetic projections from the central nervous system synapse at the stellate and thoracic ganglia, where postganglionic fibres project to the heart [1, 2]. A complex network of sympathetic neurons innervates the epicardium, with a homogeneous distribution of fibres to the entire heart. Localized varicosities (boutons) along the length of the terminal axon act as storage and release points of norepinephrine forming relatively dispersed synapses compared to central nervous system junctions [1]. Regional tissue concentrations of norepinephrine are considered the gold standard measurement of cardiac sympathetic activation. The highest norepinephrine concentration is localized to the sinoatrial node, atrioventricular node, and atria as compared to the ventricles [2]. Sympathetic stimulation of the conduction system produces elevated heart rate.

Activation of sympathetic neurons evokes release of the neurotransmitter norepinephrine into the synaptic cleft where it binds to G protein-coupled adrenoceptors at the cardiomyocyte membrane [3] (Figure 1). β-Adrenoceptors are positively coupled to stimulatory G protein Go_s, which activates the cAMP/PKA signaling cascade, culminating in enhanced Ca²⁺ influx and cardiac contractility [4]. The β2- and β3-adrenoceptor isoforms are also coupled to inhibitory G protein Go_i, which reduces cAMP production providing balance in noradrenergic signaling [3].

The sympathetic signal is terminated by active recapture of the neurotransmitter into the neuronal varicosity by the sodium-dependent norepinephrine reuptake transporter (NET) via the uptake-1 pathway [5, 6]. Norepinephrine is further packaged into neuronal vesicles by vesicular monoamine transporter-2 (VMAT2) [7, 8] or metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) [9].

Diabetic heart

Metabolic and contractile adaptation

The complex changes in metabolic and contractile cardiac function in the progression of diabetes have been extensively reviewed [10, 11]. Briefly, the diabetic heart exhibits a shift in metabolic substrate preference to almost exclusive utilization of fatty acids over glucose [12, 13]. This shift exacerbates insulin resistance [14, 15] and contributes to the accumulation of lipid metabolites [16, 17] and advanced glyca-
Imaging cardiac SNS in diabetes

Circulating factors

In addition to the compensatory activation, elevated plasma concentration of several factors have been shown to augment SNS activity. Elevated endogenous or exogenous glucose produces elevated circulating levels of norepinephrine [22-24]. Similarly, hyperinsulinemia has been linked to increased SNS activity [25, 26]. Administration of exogenous fatty acids enhances muscle sympathetic nerve activity by 45%, with resultant increases in heart rate and blood pressure [27].

Diabetic cardiac autonomic neuropathy

Diabetic autonomic neuropathy is a late stage complication of prolonged diabetes characterized by the development of neuroaxonal dystrophy, a swelling of distal neuronal axons without relative neuron loss [28]. Whereas early diabetes has been associated with elevated sympathetic tone, autonomic neuropathy results in a decrease in cardiac norepinephrine content and an accumulation of neurotrophins consistent with damage sustained by sympathetic neurons [29, 30]. Accumulation of advanced glycation end products, activation of apoptotic signals, oxidative stress, and elevated basal firing rate contribute to the degeneration of sympathetic neurons [31, 32].

SNS in diabetes

The presence of abnormal SNS signaling in the diabetic heart has been well established, as evidenced by direct and indirect measurements. It is unclear as to the order of sympathetic hyperactivity and development of insulin resistance, with some investigators purporting that insulin resistance is precipitated by a primary increase in sympathetic tone [33, 34], and others claiming independent development of insulin resistance and hyperinsulinemia promoting sympathetic drive [35]. Because of the complex interaction of SNS activity, hyperglycemia, hyperinsulinemia, metabolism, and insulin resistance it is difficult to define the primary insult. Recent clinical evaluations have attempted to define a temporal progression from sympathoadrenal activation to insulin resistance. A recent meta-analysis has suggested that SNS dysfunction is present in 51.9% of diabetic patients, but is likely underestimated due to reliance on somewhat crude tests [36].

Norepinephrine measurements

Elevated norepinephrine turnover and accumulation of neuronal norepinephrine have been found in diabetic animal models. Ganguly and colleagues demonstrated a twofold increase in cardiac and plasma norepinephrine concentration after 8 weeks of diabetes induced by streptozotocin (STZ) in rats [23]. Studies in isolated perfused diabetic hearts revealed enhanced catecholamine turnover, evidenced by elevated tyramine-induced norepinephrine release, increased initial rate of uptake of $^{3}$H-norepinephrine, and reduced half time of $^{3}$H-norepinephrine turnover. These parameters were normalized by treatment with insulin at 4 weeks after diabetes induction [23, 37]. Elevated norepinephrine levels have been described in a number of animal models and durations of diabetes, including STZ-induced type 1 diabetes [38], insulin-resistant intraperitoneal STZ-induced diabetes [24, 39], Zucker Diabetic Fatty rats [40], and non-obese Goto-Kakizaki type 2 diabetic rats [41].

These findings are supported by histofluorescence studies using glyoxylic acid, demonstrating increased fluorescent noradrenergic varicosities after 1 month of STZ-induced diabetes. In the same study, high performance liquid chromatography-quantified ventricular norepinephrine levels were elevated by 48-58% in 1 month diabetics compared to controls [42]. At 4 weeks of diabetes, STZ rats show reduced dopamine content in stellate ganglia, but an increase of ventricular norepinephrine, suggesting enhanced local conversion of neurotransmitter. No change in brain or plasma norepinephrine content was observed at this time point [43].

Sympathetic nerve activity

Electrode measurement of renal sympathetic nerve activity showed a reduced ability to adapt
to volume expansion in STZ diabetic rats compared to controls, associated with a blunted change in heart rate following phenylephrine administration [44]. Splanchnic sympathetic nerve activity response to phenylephrine was dampened in obese adult Zucker rats compared to age-matched lean Zucker rats in the absence of overt diabetes [45].

**Baroreceptor reflex**

The baroreceptor reflex is an indirect indicator of SNS activation in the heart, reflecting responsiveness to α-adrenergic stimulation. Left aortic depressor nerve activity measurements taken in OVE26 transgenic type 1 diabetic mice demonstrated a reduction in baroreflex control of heart rate in response to phenylephrine or sodium nitroprusside [46]. Pressure transducer evaluation in type 1 diabetic rats at baseline compared to non-diabetic controls describe reduced mean arterial pressure (-12%), heart rate (-13%) and lower rates of isovolumic pressure development and decay following phenylephrine challenge [47].

**Heart rate variability**

Advancement of implantable telemetry transducerreceiver technology has facilitated longitudinal analysis of sympathetic tone in diabetic rats. Power spectral analysis provides a surrogate measurement of baroreceptor reflex activity and the quantification of heart rate variability [48-51].

Heart rate variability (standard deviation of normal heart rhythm, SDNN) has been demonstrated to be reduced by 50% (18 vs 36 bpm) within days of diabetes induction by STZ compared to non-diabetic controls [52, 53]. Low frequency to high frequency power ratio progressively increased over time, suggesting declination of high frequency (parasympathetic) and mid frequency (sympathetic) density [53]. Treatment with insulin was insufficient to restore heart rate variability to control levels, though there was a modest recovery of heart rate: 362 vs 266 vs 303 bpm in non-diabetic, diabetic, and insulin-treated diabetic rats, respectively [54].

In Goto-Kakizaki non-obese type 2 diabetic rats a less prominent but significant reduction of heart rate variability SDNN compared to non-diabetic controls was observed at 2 months (-24%) and 7 months (-16%), but was attenuated at 15 months of age (-5%) [55]. This is consistent with reduced heart rate variability during aging [55], with parallel changes in NET expression and reuptake function reported [56]. The differences in heart rhythm derive in part from extended duration of electrocardiogram QRS complex with no difference in QT interval between groups [55]. Prolonged QRS is consistent with delayed repolarization as observed in STZ rats [57-59].

Continuous telemetric monitoring in db/db type 2 diabetic mice describes a blunting of baroreflex regulation of heart rate, calculated by sequence method and cross-spectral analysis. Whereas blockade of sympathetic signaling with metoprolol decreased heart rate substantively in db/db mice, the effect was negligible in db/+ mice, consistent with constitutive activation of the cardiac SNS [60]. Atropine blockade of parasympathetic tone was also blunted in db/db mice compared to db/+ controls [60]. Conversely, study of non-obese diabetic mice showed the presence of sympathetic neuropathy, evidenced by elevated baroreceptor reflex activity that was not attenuated by metoprolol administration [61]. Heart rate variability measurement demonstrated reduced standard deviation of R-R interval in db/db mice compared to db/+ controls [60].

Power spectrum density analysis of systolic arterial pressure in diabetic rats revealed a progressive reduction of intermediate frequency (0.25-0.65 Hz), the range generally corresponding to sympathetic modulation of vascular tone, remaining fairly consistent over 1 to 18 weeks after STZ induction of diabetes [62].

These findings have been replicated in the clinical population. A study of young Norwegian males demonstrated that those in the highest quartile elevation of plasma norepinephrine during cold pressor test showed elevation of fasting plasma glucose level and homeostasis model assessment of insulin resistance at 18-years follow-up. This observation suggests that early sympathetic dysfunction may partially underlie subsequent development of insulin resistance and pre-diabetes [63]. A similar result was obtained by heart rate variability analysis over 8 year follow up in the Atherosclerosis Risk in Communities (ARIC) trial. In this case, indi-
individuals falling in the lowest quartile of heart rate variability (either standard deviation of R-R interval or low-frequency power) were 60% more likely than the highest quartile to develop insulin resistance or diabetes [64]. It has been reasoned that sustained sympathetic activation may augment lipid metabolism, leading to elevated circulating fatty acids and insulin resistance [64].

### β-Adrenoceptor expression

The persistent elevation of catecholamines evokes downregulation of cardiomyocyte β-adrenoceptors, and a shift in the isoform population to favour G-coupled β2-adrenoceptors. This pattern is well characterized in the development of heart failure [65, 66], and has been extensively described in diabetes as well, including rats [67, 68], large animal models [69], and the patient population [70]. Reduced β-adrenoceptor expression has been consistently described in type 1 diabetic heart (Table 1), evidenced by significant reductions in total β-adrenoceptor binding in radioligand binding assays [67, 71-76].

Latifpour and McNeill established time dependent changes in cardiac autonomic receptor expression patterns in type 1 diabetic STZ-treated rats [75]. At 3 months of diabetes compared to age-matched non-diabetic controls, only ³H-prazosin binding to α-adrenoceptors was reduced ($B_{max}$ 66.6 vs 78.8 fmol/mg protein), with no difference in ³H-dihydroalprenolol or ³H-quinuclidinyl benzilate binding to β-adrenoceptors and muscarinic cholinergic receptors, respectively. By 6 months of untreated diabetes, binding to all three receptors was reduced by 21-28% ($α$-adrenoceptor: 56.4 vs 72.2; $β$-adrenoceptor: 22.5 vs 28.6; muscarinic: 84.8 vs 117.4 fmol/mg protein) [75].

Reduced $β$-adrenoceptor density in diabetes reflects a shift in relative expression of $β$-adrenoceptor subtypes as determined by Western immunoblotting [67]. Quantification of Coomassie staining showed a shift in $β1;β2;β3$ expression profile from 62:30:8 in control to 40:36:23 in diabetic rat hearts [67]. This shift is similar to that observed during sympathetic hyperactivity in the development of heart failure [65]. In the same study, normalization of blood glucose by daily insulin injection for only 2 weeks following 12 weeks of chronic diabetes was sufficient to revert expression patterns to

### Table 1. $β$-Adrenoceptor Expression in Diabetic Heart

<table>
<thead>
<tr>
<th>Diabetic Model</th>
<th>Duration</th>
<th>Measurement</th>
<th>Isoform(s)</th>
<th>$B_{max}^{*}$</th>
<th>% Diff†</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD, alloxan 35 mg/kg iv</td>
<td>5 days</td>
<td>³H-DHA binding</td>
<td>all</td>
<td>47±4</td>
<td>-51%</td>
<td>[74]</td>
</tr>
<tr>
<td>SD, STZ 65 mg/kg ip</td>
<td>2 weeks</td>
<td>³H-DHA binding</td>
<td>all</td>
<td>35±4</td>
<td>-6%</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CGP20712 block, high affinity</td>
<td>$β_1AR$</td>
<td>10±1</td>
<td>-46%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CGP20712 block, low affinity</td>
<td>$β_2AR$</td>
<td>24±1</td>
<td>+37%</td>
<td></td>
</tr>
<tr>
<td>WK, STZ 45 mg/kg iv</td>
<td>4-6 weeks</td>
<td>³H-CGP12177 binding</td>
<td>all</td>
<td>33±7</td>
<td>-51%</td>
<td>[72]</td>
</tr>
<tr>
<td>WK, STZ 60 mg/kg iv</td>
<td>6 weeks</td>
<td>Western immunoblotting</td>
<td>$β_1AR$</td>
<td>-65%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$β_2AR$</td>
<td>+61%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$β_3AR$</td>
<td>+140%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WK, STZ 55mg/kg iv</td>
<td>8 weeks</td>
<td>¹²⁵I-CYP binding</td>
<td>all</td>
<td>36±4</td>
<td>-31%</td>
<td>[73]</td>
</tr>
<tr>
<td>SHR, STZ 55 mg/kg iv</td>
<td>8 weeks</td>
<td>¹²⁵I-CYP binding</td>
<td>all</td>
<td>35±5</td>
<td>-34%</td>
<td>[73]</td>
</tr>
<tr>
<td>SD, STZ 45 mg/kg ip,</td>
<td>8 weeks</td>
<td>³H-CGP12177 ex vivo biodist.</td>
<td>all</td>
<td>-40%</td>
<td></td>
<td>[127]</td>
</tr>
<tr>
<td>high fat feeding</td>
<td></td>
<td>Western immunoblotting</td>
<td>$β_1AR$</td>
<td>-15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$β_2AR$</td>
<td>+12%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Western immunoblotting</td>
<td>$β_3AR$</td>
<td>+20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SD, STZ 65 mg/kg iv</td>
<td>10 weeks</td>
<td>³H-CGP12177 binding</td>
<td>all</td>
<td>92±4†</td>
<td>-41%</td>
<td>[76]</td>
</tr>
<tr>
<td>WK, STZ 45 mg/kg iv</td>
<td>14 weeks</td>
<td>Western immunoblotting</td>
<td>$β_1AR$</td>
<td>-45%</td>
<td></td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$β_2AR$</td>
<td>-17%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$β_3AR$</td>
<td>+200%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SD, STZ 65 mg/kg iv</td>
<td>13 weeks</td>
<td>³H-DHA binding</td>
<td>all</td>
<td>28±3</td>
<td>-13%</td>
<td>[75]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23±2</td>
<td>-21%</td>
<td></td>
</tr>
</tbody>
</table>

* fmol/mg protein; † (Diabetic – Control) / Control × 100%; ‡ fmol/10⁶ cells. SD, Sprague Dawley rat; WK, Wistar Kyoto rat; SHR, Spontaneously Hypertensive Rat; DHA, dihydroalprenolol; ¹²⁵I-CYP, ¹²⁵I-cyanopindolol; biodist, biodistribution
normal, with a $\beta_1;\beta_2;\beta_3$ expression profile of 57:33:10 [67]. Displacement of $^3$H-dihydroalprenolol by cold CGP20712 to distinguish high affinity $\beta_1$-adrenoceptor binding from low affinity $\beta_2$-adrenoceptor identified a shift in relative expression ($\beta_1;\beta_2$) from 52:48 in control to 30:70 in untreated diabetics, restored to 40:60 by insulin [68]. These findings establish the critical involvement of glycemia in the maintenance of $\beta$-adrenoceptor expression.

After 2.5 months of diabetes, internalization of $\beta$-adrenoceptors is evident, as determined by binding assays with the cell-surface impermeable $^3$H-CGP12177 compared to lipophilic $^{125}$I-iodocyanopindolol [76]. This observation suggests an increase in the internalization of $\beta$-adrenoceptors during diabetes, prior to overt degradation, which, in the context of other dihydroalprenolol studies, is suggested to occur by 6 months of diabetes. Treatment over 48 hours with insulin partially restored membrane surface $^3$H-CGP12177 binding sites [76]. The rapid response to insulin suggests that early internalization and impairment of $\beta$-adrenoceptor signaling is readily reversible by glycemic control.

The altered expression patterns of myocardial $\beta$-adrenoceptors bear functional consequences. The reduced maximum rate of left ventricle $dP/dt_{\text{max}}$ was associated with a reduction of isoproterenol-induced adenylate cyclase activity after 4 weeks of untreated diabetes, suggesting alteration of upstream signaling mediators [71]. Paradoxically, pressure transducer evaluation in type 1 diabetic rats following administration of low-dose $\beta_1$-adrenoceptor agonist dobutamine (1 $\mu$g/kg) showed nearly double maximal isovolumic pressure development and decay compared to controls. Insulin treatment normalized the response in diabetic rats. This suggests an increased sensitivity to $\beta$-adrenergic stimulation, consistent with an upregulation of $\beta_1$-adrenoceptors [47]. However, no attempt to quantify adrenoceptors was performed in this study.

In isolated perfused diabetic hearts (6 weeks post STZ), left ventricular developed pressure was significantly lower than controls by as much as 50% at higher left atrial filling pressure, associated with a 50% reduction in relative $\beta_1$-adrenoceptor expression [77]. Treatment with the $\beta_1$-adrenoceptor antagonist metoprolol not only increased expression of $\beta$-adrenoceptors in diabetic hearts, but also improved mechanical performance in left ventricular pressures [77]. Sharma and colleagues further demonstrated concomitant improvement in metabolic performance in metoprolol-treated rats, characterized by an 80% increase in glucose oxidation, 39% decrease of palmitate oxidation, driven in part by a reduction in carnitine palmitoyl transferase-1B expression and activity [78, 79].

**Downstream noradrenergic signaling**

In addition to changes in innervation and receptors, downstream targets of the SNS have also been studied in diabetes. As early as 8 days after diabetes induction, the response of adenylate cyclase to $\beta$-adrenergic stimulation was ablated, whereas other pathways of adenylate cyclase activation remained intact [80]. No difference in dihydroalprenolol binding was observed [80], suggesting a functional uncoupling of adenylate cyclase from myocardial $\beta$-adrenoceptors. Additional evidence suggests that adenylate cyclase and cAMP inotropic effects are independently impaired in diabetes, with reduced contractile force observed in isolated perfused hearts following stimulation with adenylate cyclase activator forskolin, exogenous dibutyryl cAMP, or 3-isobutyl-1-methylxanthine (IBMX) [81]. Reduced expression of $\beta$-adrenoceptors in isolated perfused 4 week diabetic heart also affects calcium mobilization, wherein diabetic rats exhibit lower intracellular Ca$^{2+}$ following stimulation with isoproterenol [82]. This anomaly would impair the contractile response to sympathetic stimulation and stress.

**SNS imaging targets with PET and SPECT**

Tracer-based imaging of the SNS has gained traction in recent years, progressing toward more mainstream clinical application. Targets of molecular imaging include evaluation of neuron integrity at the NET and evaluation of postsynaptic expression of $\beta$-adrenoceptors at the cardiomyocyte membrane (reviewed in [9, 83]) (Figure 2A). Additional autonomic targets include muscarinic receptors [84], angiotensin II type 1 receptors [85, 86] and intracellular signaling elements phosphodiesterase-4 [87] and diacylglycerol [88], though the validation of these tracers is at present unclear [89]. The bulk of SNS imaging has been focused on pre-synaptic measurements of reuptake function and postsynaptic adrenoceptor density.
Neuronal imaging agents are generally analogues of norepinephrine (Figure 2B), that are taken up via the sodium-dependent NET (uptake-1) pathway. In SPECT, the prevalent tracer is radio-iodinated metaiodobenzylguanidine (123I-MIBG). Availability and regulation has limited 123I-MIBG use to research purposes, but recent advances have revealed an added-value of neuronal imaging using 123I-MIBG among heart failure patients, which may accelerate its application as a clinical diagnostic tool [90, 91]. In PET, 11C-meta-hydroxyephedrine (11C-HED), 11C-phenylephrine, and 11C-epinephrine have been evaluated with varying degrees of success (reviewed in [9, 92]). The development, characterization, and application of these radiotracers have been extensively studied and reviewed [9, 92, 93].

**123I-MIBG SPECT imaging**

Briefly, retention of 123I-MIBG was shown to be reduced by blockade of NET (uptake-1) [94] and following sympathectomy by phenol application in the canine heart [95], though a high degree of extraneuronal uptake (via uptake-2) is consistently observed in many animal species. Heart transplant recipients reflect this observation, with a complete lack of early and late 123I-MIBG uptake by myocardium devoid of sympathetic innervation [9]. 123I-MIBG has been applied in nuclear cardiology to examine post-myocardial infarct healing [96, 97], arrhythmia [98, 99], and progression of congestive heart failure [100]. Reduced contrast between the heart and the mediastinum is characteristic of impaired neuronal function, which also manifests as enhanced late tracer washout [90, 98, 101].

**11C-HED PET imaging**

Advantages of the PET tracer 11C-HED include high neuronal compared to extraneuronal uptake [102], long neuronal retention time due to partial packaging in vesicles [103], and metabolic stability due to resistance to catecholamine metabolism by MAO or COMT [104]. Due to high neuronal compared to extraneuronal uptake [102], long neuronal retention time due to partial packaging in vesicles [103], and metabolic stability due to resistance to catecholamine metabolism by MAO or COMT [104].
to its lipophilicity, $^{11}$C-HED can passively diffuse from the neuronal varicosity, and is also subject to active release during signal transduction. Kinetic studies have demonstrated the dependence of $^{11}$C-HED retention on the availability of NET, established as susceptibility to blockade or displacement by the NET inhibitor desipramine. This has been observed in isolated perfused rat heart [94], ex vivo biodistribution in rats [105-107] and dogs [94, 108] and more recently using small animal PET in rats [93] and mice [109]. Retention of $^{11}$C-HED is also subject to competition for limited reuptake sites with endogenous and exogenous neurotransmitter, as demonstrated by treatments with the precursor and false neurotransmitter metaraminol [107, 109], treatments to enhance endogenous norepinephrine such as tranylcypromine [105] and by infusion of exogenous norepinephrine [105]. Clinical applications of $^{11}$C-HED have included post-infarct neuronal remodeling [110], tracking of post-transplant reinnervation [111, 112], arrhythmia [113, 114], congestive heart failure [115-117], hibernating myocardium [118, 119], hypertrophic cardiomyopathy [120], and coronary artery disease [121]. Evaluation of $^{11}$C-HED in rats (Figure 3A) has demonstrated similar image quality to clinical images (Figure 3B), though accelerated tracer washout due to heightened basal sympathetic tone is observed in rats compared to humans [93].

$^{11}$C-Phenylephrine is subject to metabolism by MAO to $^{11}$C-methylamine, complicating kinetic modeling [93, 122]. $^{11}$C-Epinephrine holds promise as a sympathetic neuronal marker with the added complication of labeled metabolites [93, 123]. Retention properties of both of these tracers are similar to $^{11}$C-HED, with advantageous and disadvantageous characteristics (reviewed in [9]). Effectively, retention of $^{123}$I-MIBG or $^{11}$C-HED provides a dynamic semi-quantitative measurement of reuptake, storage, and release of norepinephrine from myocardial sympathetic neuronal varicosities.

$^{11}$C-CGP12177 PET imaging

Non-invasive determination of $\beta$-adrenoceptor density is another target of interest in imaging the cardiac SNS. The bulk of research has been conducted using the non-selective $^{11}$C-CGP12177 and its derivatives (Figure 2B). Labeled with tritium, CGP12177 has been utilized in binding assays to determine $\beta$-adrenoceptor density ex vivo [124, 125]. As a radiotracer, CGP12177 shows high and sustained uptake in myocardium compared to surrounding tissues in rat hearts, and is selectively blocked up to 90% by $\beta$-blockers propranolol, atenolol and unla-beled compound [126, 127]. Complicated synthesis has limited the use of $^{11}$C-CGP12177 to some extent, though some clinical applications

Figure 3. Sample $^{11}$C-HED myocardial images. (A) Rat $^{11}$C-HED coronal image obtained using Siemens Inveon DPET small animal camera showing heart and liver uptake. (B) Reoriented $^{11}$C-HED PET cardiac image from a patient with obstructive sleep apnea obtained using GE Discovery D690 PET/VCT 64 camera.
have emerged, including use in post-myocardial infarction [128], heart failure [117, 129], hibernating myocardium [119], and non-ischemic cardiomyopathy [130, 131]. A correlation has been described between pre- and post-synaptic function, as assessed with $^{11}$C-HED and $^{11}$C-CGP12177, respectively, with similar reduction in sympathetic neuron integrity and myocardial β-adrenoceptor density observed among subjects with congestive heart failure [116, 129]. A similar correlation was described to early and delayed late heart-to-mediastinal ratio of $^{123}$I-MIBG [131]. In a small scale trial in patients with stable chronic heart failure due to idiopathic cardiomyopathy, β-adrenoceptor density measured by $^{11}$C-CGP12177 PET predicted 20 month response to carvedilol treatment, wherein the patients with the lowest CGP12177 binding showed the greatest improvement in left ventricular ejection fraction [130]. Application of CGP12177 in the diabetic heart has been limited to preclinical evaluations, but ex vivo biodistribution studies suggest that CGP12177 is a suitable radiotracer for longitudinal evaluation of β-adrenoceptor density in the diabetic heart [127].

(R)-$^{11}$C-Rolipram PET imaging

(R)-$^{11}$C-Rolipram (Figure 2B) has been characterized in small animals for evaluation of phosphodiesterase-4 expression in the heart, providing an indirect index of intracellular cAMP activation. Preliminary evaluation of (R)-$^{11}$C-rolipram imaging has illustrated quality myocardium-to-blood and myocardium-to-background contrast and specific binding in rats (Figure 4AB) and dogs (Figure 4C) [132, 133]. Cardiac binding of (R)-$^{11}$C-rolipram was enhanced by treatments elevating endogenous norepinephrine and reduced when phosphodiesterase-4 is blocked [133, 134]. By contrast in animal models of chronic obesity and acute adriamycin-induced cardiotoxicity, characterized by elevated sympathetic drive and catecholamine levels, no increase in (R)-$^{11}$C-rolipram cardiac binding was observed in response to blockade of the NET by desipramine and increased synaptic norepinephrine [135, 136]. This finding is consistent with downregulation of β-adrenoceptors.

Preclinical imaging of SNS in diabetes

The development of specific radiotracers and dedicated small animal imaging systems has facilitated the interrogation of cardiac sympathetic nervous integrity in rodent models of diabetes using SPECT and PET imaging, ex vivo biodistribution, and autoradiography techniques (Table 2).

$^{123}$I-MIBG preclinical imaging in diabetes

A small number of preliminary imaging studies have been conducted using radiiodinated $^{123}$I-MIBG.
MIBG in diabetic rodents. Small animal SPECT imaging revealed maintained uptake but enhanced myocardial washout of $^{123}$I-MIBG over 30-120 min after injection among STZ diabetic C57/Bl6 mice compared to controls (41 vs 21%). Liver washout and urinary excretion were also accelerated. $^3$H-Desipramine binding assay demonstrated a reduction of NET density ($B_{\text{max}}$) in hearts of diabetic compared to non-diabetic mice (136 vs 244 fmol/mg protein) with no change in binding affinity ($k_d$) [137]. Maintained initial uptake with enhanced washout suggests the presence of functional sympathetic nerve terminals and elevated sympathetic tone, with downregulation of NET consistent with other models of diabetes [24, 41].

Similar observations were made using pinhole SPECT studies in Wistar STZ rats, with washout acceleration to 21.0 as compared to 12.8 %/h in non-diabetic controls [138]. Evaluation of $^{123}$I-MIBG in STZ rats at 8 weeks demonstrated reduced uptake at 60 min after injection compared to age-matched healthy controls and accelerated washout over 4 hours (36 vs 22%). The altered tracer kinetics were corroborated by an elevation of plasma norepinephrine (3.6 vs 2.4 nmol/l) and reduced β-adrenoceptor expression measured by $^3$H-cyanopindolol binding assay (36 vs 52 fmol/mg protein) [139]. In comparing Zucker obese with lean rats at 22 weeks of age, obese animals displayed higher initial uptake of $^{123}$I-MIBG (0.67 vs 0.18 counts × kg body weight / pixel × injected dose). However, the washout was significantly accelerated in obese compared to lean rats (44 vs 19%) [139]. No change in norepinephrine was observed, but β-adrenoceptor density was 15% lower in Zucker obese rats.

In ex vivo studies, regional distribution of $^{123}$I-MIBG was compared with sestamibi (MIBI) using autoradiographic techniques in STZ diabetic rats to discern sympathetic neuronal density and perfusion, respectively. A decrease in inferior wall $^{123}$I-MIBG distribution absorption ratio was observed in 10 week diabetic rats, with no comparable decrease observed in MIBI distribution. By contrast, no difference was reported in control rats. These observations correlated to an increase in regional norepinephrine levels in diabetic compared to non-diabetic rats (8.2 vs 4.3 μg/g anterior wall; 8.7 vs 3.9 μg/g inferior wall) and a moderate decrease in inferior wall NET density (641 vs 809 fmol/mg protein) as measured by $^3$H-desipramine binding assay [140]. This suggests that while blood flow was maintained, a regional impairment of anterior sympathetic innervation was apparent. In non-obese type 2 diabetic Goto-Kakizaki rats (8 weeks old), the same investigators described maintained MIBI and a moderate decrease in

### Table 2. Summary of Preclinical Myocardial Presynaptic Imaging Studies in Diabetic Rodents

<table>
<thead>
<tr>
<th>Model</th>
<th>Duration</th>
<th>Tracer</th>
<th>Method</th>
<th>Finding</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD, STZ 55 mg/kg iv</td>
<td>4 weeks</td>
<td>$^{123}$I-MIBG</td>
<td>ex vivo autoradiography</td>
<td>-13% inferior LV retention</td>
<td>[140]</td>
</tr>
<tr>
<td>SD, STZ 45 mg/kg ip, high fat feeding</td>
<td>8 weeks</td>
<td>$^{11}$C-HED</td>
<td>ex vivo biodistribution</td>
<td>-12% LV retention</td>
<td>[24]</td>
</tr>
<tr>
<td>WK, STZ 50 mg/kg ip</td>
<td>6 months</td>
<td>$^{11}$C-HED</td>
<td>ex vivo biodistribution</td>
<td>-33% distal LV retention</td>
<td>[30]</td>
</tr>
<tr>
<td></td>
<td>9 months</td>
<td>$^{11}$C-HED</td>
<td>ex vivo biodistribution</td>
<td>-40% proximal LV retention</td>
<td>[30]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$^{11}$C-HED</td>
<td>ex vivo biodistribution</td>
<td>-44% distal LV retention</td>
<td>[30]</td>
</tr>
<tr>
<td>Goto Kakizaki</td>
<td>8 weeks</td>
<td>$^{123}$I-MIBG</td>
<td>ex vivo autoradiography</td>
<td>-23% anterior LV retention</td>
<td>[41]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$^{123}$I-MIBG</td>
<td>pinhole SPECT</td>
<td>-41% inferior LV retention</td>
<td>[139]</td>
</tr>
<tr>
<td>WK, STZ 60 mg/kg iv</td>
<td>8 weeks</td>
<td>$^{123}$I-MIBG</td>
<td>pinhole SPECT</td>
<td>-58% counts x kg / pixel</td>
<td>[139]</td>
</tr>
<tr>
<td>SHR, STZ 60 mg/kg</td>
<td>8 weeks</td>
<td>$^{123}$I-MIBG</td>
<td>pinhole SPECT</td>
<td>+61% washout rate</td>
<td>[139]</td>
</tr>
<tr>
<td>Zucker Obese</td>
<td>22 weeks</td>
<td>$^{123}$I-MIBG</td>
<td>pinhole SPECT</td>
<td>+272% counts x kg / pixel</td>
<td>[139]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$^{123}$I-MIBG</td>
<td>pinhole SPECT</td>
<td>+44% washout rate</td>
<td>[139]</td>
</tr>
<tr>
<td>WK, STZ 60 mg/kg iv</td>
<td>8 weeks</td>
<td>$^{123}$I-MIBG</td>
<td>small animal SPECT</td>
<td>+64% washout rate</td>
<td>[138]</td>
</tr>
<tr>
<td>mice, STZ 35 mg/kg ip × 5 d</td>
<td>7 months</td>
<td>$^{123}$I-MIBG</td>
<td>small animal SPECT</td>
<td>+95% LV washout rate</td>
<td>[137]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$^{123}$I-MIBG</td>
<td>small animal SPECT</td>
<td>+14% initial LV uptake</td>
<td>[137]</td>
</tr>
</tbody>
</table>

SD, Sprague Dawley; WK, Wistar Kyoto; SHR, Spotaneously Hypertensive Rat; $^{123}$I-MIBG, metaiodobenzylguanidine; $^{11}$C-HED, hydroxyephedrine
Imaging cardiac SNS in diabetes

125I-MIBG inferior to anterior wall distribution absorption ratio. No difference in regional cardiac norepinephrine concentration was detected between Goto-Kakizaki and non-diabetic rats, but a dramatic reduction of NET density was observed by binding assay (263 vs 364 fmol/mg protein anterior wall; 251 vs 459 fmol/mg protein inferior wall) [41].

11C-HED preclinical imaging in diabetes

Distribution of 11C-HED has been assessed in STZ-induced diabetic rats using gamma counting techniques. At 6 months of diabetes, STZ rats exhibited a significant 33% reduction of 11C-HED retention restricted to the distal left ventricle compared to non-diabetic controls, with a mild but significant increase in left ventricle norepinephrine (711 vs 600 ng/g proximal; 613 vs 491 ng/g distal). By 9 months of diabetes, this defect was observed in the entire left ventricle, with reduced HED accumulation by 40-44% in proximal and distal left ventricle segments. At the 9 month timepoint, significant reduction of norepinephrine (503 vs 694 ng/g proximal; 351 vs 536 ng/g distal) and nerve growth factor (4.1 vs 10.1 ng/g proximal; 2.9 vs 7.4 ng/g distal) was described. Taken together these data indicated that while autonomic neuropathy was present at 9 months, this was preceded (at 6 months) by a regional dysregulation of sympathetic neurons during which norepinephrine release was not impeded [30].

A similar result was obtained at 2 months of diabetes in STZ diabetic rats fed high fat diet to produce insulin resistance. Retention of 11C-HED in cardiac regions was globally reduced by 15-30%, with a corresponding increase in cardiac norepinephrine levels (20%) and a decrease in NET expression (-17%) compared to age-matched, high fat diet-fed controls. Immunostaining for tyrosine hydroxylase confirmed the maintenance of intact sympathetic neurons in the left ventricle of diabetic rats [24]. Collectively, these studies have built a foundation for further longitudinal evaluation of sympathetic neurons during which norepinephrine release was not impeded [30].

Clinical imaging of SNS in diabetes

123I-MIBG clinical imaging in diabetes

SNS imaging studies in the diabetic patient population have largely been limited to investigation of presynaptic nervous integrity using 123I-MIBG SPECT or 11C-HED PET. Evaluation of postsynaptic β-adrenoceptors in human subjects has been limited. The trials have overwhelmingly focused on type 1 diabetes and the development of autonomic neuropathy, though some instances of early sympathetic dysregulation in diabetes have also been described (Table 3).

Mean late heart-to-mediastinal ratio of 123I-MIBG uptake was significantly lower in diabetic subjects compared to non-diabetic subjects, regardless of heart failure progression. Among diabetic patients, lower heart-to-mediastinal 123I-MIBG late uptake ratio (<1.60) was associated with three times greater rate of heart failure progression as compared to diabetic patients with a normal (>1.60) heart-to-mediastinal 123I-MIBG uptake ratio (33.5 vs 11.2% event rate) [141]. There was no difference in plasma norepinephrine levels between diabetic and non-diabetic subjects, suggesting greater prognostic
Imaging cardiac SNS in diabetes

Greater impairment in baroreflex sensitivity was found among hypertensive type 2 diabetic patients as compared to normotensive diabetics, paralleled by a modest decrease in 123I-MIBG uptake (heart-to-mediastinum ratio) at early and delayed stages and an increased washout rate [142]. No difference in high and low frequency power heart rate variability or plasma norepinephrine was found between these subgroups of diabetics [142].

In a study of 114 patients, autonomic function testing by heart rate variability and reflex tests identified 16 patients with cardiac autonomic neuropathy. Patients with neuropathy exhibited a modest decrease in 123I-MIBG heart-to-mediastinal ratio compared to those without (1.6 vs 1.8) which significantly correlated with reduced resting tissue Doppler peak early diastolic velocity (4.7 vs 6.3 cm/s) [143]. Regional analysis demonstrated denervation particularly localized to the anterior and lateral walls of the ventricle [143].

11C-HED clinical imaging in diabetes

Stevens and colleagues described a defect in 11C-HED retention in ~7-9% of the distal left ventricle of diabetic patients, consistent with sympathetic denervation or dysinnervation [144]. At 3 years follow up, among patients who subsequently achieved good glycemic control this deficit of 11C-HED retention index was reduced by 77% compared to the first scan, and average retention index score in proximal and distal segments improved by 30%. By contrast, among patients with poor glycemic control the size of the apical defect was increased by 340%, with distal segments showing a further 21% decrease in retention index [144]. Interestingly, no improvement in autonomic reflex test scores was observed among the patients with good glycemic control [144]. A similar capacity for recovery was shown in a 1 year follow-up scintigraphy study among type 1 diabetic patients, wherein patients achieving glycosylated hemoglobin <8% exhibited significant reduction of global and regional 123I-MIBG uptake score [145].

In the presence of coronary artery disease, fixed defects of 11C-HED retention remain, but were not complicated by the presence of diabetes. The defect size of 11C-HED did not increase in size or severity over a 1 year follow up among coronary artery disease patients during normal therapy [146]. These patients exhibited good glucose control, with HbA1c levels of 6.9±0.9%, matching the cutoff value for glycemic control previously identified [144]. However, in seg-

Table 3. Summary of Clinical Myocardial Presynaptic Imaging Studies in Diabetic Patients

<table>
<thead>
<tr>
<th>Tracer</th>
<th>N</th>
<th>Groups</th>
<th>Finding</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>11C-HED</td>
<td>10</td>
<td>type 1 diabetic</td>
<td>reduced retention index (-30%) in diabetics</td>
<td>[144]</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>healthy controls</td>
<td>increased retention index (+25%) 3 y follow-up, good control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>diabetic</td>
<td>decreased retention index (-14%) 3 y follow-up, poor control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>non-diabetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11C-HED</td>
<td>16</td>
<td>diabetic MNA</td>
<td>increased area of retention defects (36% of LV) in MNA patients</td>
<td>[147]</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>diabetic</td>
<td>compared to diabetic controls (&lt;1% of LV)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>non-diabetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11C-HED</td>
<td>23</td>
<td>CAD</td>
<td>slightly lower retention (-2.5%, p=0.0007) at 1 y follow up in diabetic CAD patients</td>
<td>[146]</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>type 2 diabetic</td>
<td>no change in non-diabetic CAD patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>non-diabetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>123I-MIBG</td>
<td>11</td>
<td>diabetic</td>
<td>reduced 1-y follow-up uptake score in poor glucose control</td>
<td>[145]</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>diabetic</td>
<td>no change 1 y follow-up 123I-MIBG uptake in good glucose control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>non-diabetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>123I-MIBG</td>
<td>7</td>
<td>CAN</td>
<td>reduced H/M ratio in CAN patients</td>
<td>[143]</td>
</tr>
<tr>
<td></td>
<td>26</td>
<td>healthy controls</td>
<td>correlation of H/M ratio to early diastolic tissue velocity (r^2=0.32, p=0.01)</td>
<td></td>
</tr>
<tr>
<td>123I-MIBG</td>
<td>33</td>
<td>type 2 diabetic</td>
<td>enhanced washout in hypertensive diabetic (+20%)</td>
<td>[142]</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>hypertensive</td>
<td>lower H/M ratio in hypertensive diabetic (-14%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>normotensive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>123I-MIBG</td>
<td>961</td>
<td>NYHA II-III</td>
<td>lower H/M ratio in diabetics vs non-diabetics</td>
<td>[141]</td>
</tr>
<tr>
<td></td>
<td>343</td>
<td>diabetic</td>
<td>lower H/M ratio in diabetics with heart failure progression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>618</td>
<td>non-diabetic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MNA, microangiopathy; CAD, coronary artery disease; CAN, cardiac autonomic neuropathy; H/M heart-to-mediastinal ratio
ments with severely reduced coronary flow reserve, a significant reduction of $^{11}$C-HED retention was observed, which was purported to reflect ischemic rather than hyperglycemic neuronal damage [146]. Indeed, in a small cohort Pop-Busui and colleagues identified a significant difference in $^{11}$C-HED retention as affected area among type 1 diabetic patients with early microangiopathy as compared to the stable patient population. Diabetic patients showed generally lower plasma norepinephrine levels at rest, an amplified response to the cold pressor test, baroreceptor reflex impairment, and echocardiographic indicators of diastolic dysfunction [147]. In addition, myocardial blood flow reserve was reduced in diabetics compared to healthy subjects, and reduced further in the diabetic group with early microangiopathy [147]. This loss of flow reserve may derive from loss of vascular response to norepinephrine stimulation, consistent with constitutively hyperactivated sympathetic nervous drive. Together, these observations support the presence of abnormal noradrenergic signaling and presynaptic sympathetic function even in the absence of diabetic autonomic neuropathy.

Recent clinical investigations with $^{123}$I-MIBG have made a strong case for the prognostic value of molecular imaging of the cardiac SNS. Heart-to-mediastinal uptake ratio of $^{123}$I-MIBG (<1.60 threshold) was independently predictive of heart failure progression, arrhythmic events, cardiac death, and all-cause mortality among a heart failure patient population over a two year period [90]. While this study did not directly evaluate the benefit of $^{123}$I-MIBG imaging in these patients, it provides a solid foundation for the use of sympathetic imaging data in the stratification of patient risk to inform long term treatment options. Subjects with events had a modest elevation of plasma norepinephrine compared with event-free subjects (722 vs 642 pg/ml), but norepinephrine levels alone were not of prognostic value in the study [90]. In previous reports, plasma norepinephrine has been identified as an independent predictor of cardiac events in heart failure patients [148]. Collectively, the clinical data strongly support the utility of $^{123}$I-MIBG SPECT and $^{11}$C-HED PET imaging in stratifying risk of cardiovascular events among diabetic patients, particularly progression to heart failure and sudden cardiac death. The regression of sympathetic defects to glycemic control underscores the relationship between hyperglycemia, norepinephrine, and cardiac noradrenergic signaling, and suggests that altered regulation of sympathetic neuronal signaling precedes overt neuropathy.

Future perspectives

Considerable evidence from basic and clinical studies have established the presence of abnormal SNS signaling in the diabetic heart, as both a consequence and cause of systolic and diastolic dysfunction. Diabetes evokes elevated systemic and cardiac norepinephrine, leading to blunted baroreceptor adrenergic reflex, reduced heart rate variability, and downregulation of signaling elements including presynaptic NET and postsynaptic $\beta$-adrenoceptors (Figure 5). These abnormalities partially underlie the added risk of cardiovascular morbidity and mortality incurred by the diabetic population. As molecular imaging research in this area progresses, a number of opportunities and questions stand to be addressed.

As discussed in this review, the bulk of present studies have focused on the development of sympathetic neuronal changes in type 1 diabetes, with limited imaging and non-imaging evaluation in the type 2 diabetic population. Preclinical imaging studies in established models of type 2 diabetes may provide additional insight into the progression of autonomic neuropathy and sympathetic signaling abnormalities in the development of diabetes. Some evidence suggests that neuropathy is either delayed or absent in this population, providing the opportunity to study sympathetic hyperactivity and increased myocardial norepinephrine release and the effects of therapies to dampen this sympathetic signal.

The continued development of micro imaging techniques will permit a longitudinal assessment of diabetes progression in small animal models. Basic research suggests that denervation is preceded by a transient period of sympathetic hyperactivity, which may contribute to the deterioration of myocardial performance. Serial studies in diabetic animals would facilitate the complementary analysis of sympathetic neuronal imaging, functional measures such as echocardiography and left ventricular hemodynamics, and in vitro determination of pathologi-
Imaging cardiac SNS in diabetes

Figure 5. Schematic of sympathetic nervous activation in diabetes and physiological consequences. Shift in myocardial metabolism to fatty acids over glucose stimulate nonesterified fatty acid (NEFA) accumulation and insulin resistance, elevated glucose and insulin levels, and accumulation of lipid metabolites, collagen, and advanced glycation end products (AGE), leading to reduced left ventricular compliance and SNS activation. Chronic elevation of NE leads to downregulation of NET and β-adrenoceptors with several functional consequences.

...cal mechanisms. These studies can be further translated to clinical imaging application, wherein cardiovascular risk may be identified by PET or SPECT.

In addition to established imaging of sympathetic nervous integrity ($^{11}$C-HED, $^{123}$I-MIBG) and β-adrenoceptor density ($^{11}$C-CGP12177), continuing research can explore novel neurohormonal targets in diabetes. Indirect measurements of cAMP levels by (R)-$^{11}$C-rolipram may provide a complementary measurement of sympathetic tone in diabetes. While the majority of research to date has focused on the sympathetic signaling axis, changes in parasympathetic neuronal signaling may also play a role in diabetic cardiac risk. Evaluation of myocardial muscarinic receptors using $^{11}$C-methylquinuclidinyl benzilate ($^{11}$C-MQNB) may provide additional information on cardiac function in diabetes. The development of $^{11}$C-labeled angiotensin II type 1 receptor antagonists provide the opportunity for dynamic evaluation of altered angiotensin II signaling, which partially regulates sympathetic tone. Moreover, diabetic patients treated with angiotensin II type 1 receptor blockers have been shown to exhibit improved cardiovascular outcomes.

In the long term, the literature demonstrates that abnormalities in SNS signaling identified using PET and SPECT imaging may be of value in the identification of diabetic patients at greatest risk of cardiac disease, even prior to the development of autonomic neuropathy. Given the link between hyperglycemia and elevated norepinephrine, sympathetic neuronal imaging may be further applied to evaluate myocardial
Imaging cardiac SNS in diabetes

effects of, and thereby guide, anti-diabetic therapy.

Acknowledgement

JTT held a Doctoral Research Award from the Heart and Stroke Foundation of Canada. RSB is a Heart and Stroke Foundation of Canada Career Investigator, Tier 1 University of Ottawa Chair in Cardiovascular Disease Research, and the Goldfarb Chair in Cardiac Imaging Research.

Address correspondence to: Dr. Jean DaSilva, National Cardiac PET Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada, K1Y 4W7 Tel: 613-798-5555 x 19704; Fax: 613-761-5406; E-mail: JDasilva@ottawaheart.ca

References


Imaging cardiac SNS in diabetes


Imaging cardiac SNS in diabetes


[70] Swan JW, Anker SD, Walton C, Godsland IF,


Imaging cardiac SNS in diabetes


[134] Kenk M, Greene M, Thackeray J, Dekemp RA, Lortie M, Thorn S, Beanlands RS and Dalisva JN. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the
Imaging cardiac SNS in diabetes


